[NESTLE] QoQ Cumulative Quarter Result on 30-Sep-2009 [#3]

Stock
[NESTLE] NESTLE (M) BHD
Announcement Date
29-Oct-2009
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2009
Quarter
30-Sep-2009 [#3]
Profit Trend
QoQ- 42.93%
YoY- 0.74%
Quarter Report
Latest QR
Upcoming QR
NESTLE's Result
NESTLE's Financial Summary
View:
Show?
Cumulative Result
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
Revenue 2,071,350 1,020,487 3,744,233 2,793,601 1,906,789 983,932 3,877,068 -34.23%
PBT 288,088 170,617 440,261 341,086 234,675 130,404 441,353 -24.81%
Tax -49,136 -31,819 -88,468 -75,517 -48,866 -30,050 -100,466 -38.00%
NP 238,952 138,798 351,793 265,569 185,809 100,354 340,887 -21.14%
-
NP to SH 238,952 138,798 351,793 265,569 185,809 100,354 340,887 -21.14%
-
Tax Rate 17.06% 18.65% 20.09% 22.14% 20.82% 23.04% 22.76% -
Total Cost 1,832,398 881,689 3,392,440 2,528,032 1,720,980 883,578 3,536,181 -35.56%
-
Net Worth 579,206 710,521 567,483 597,969 513,530 616,805 515,891 8.04%
Dividend
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
Div 117,248 - 351,746 117,249 117,244 - 448,333 -59.20%
Div Payout % 49.07% - 99.99% 44.15% 63.10% - 131.52% -
Equity
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
Net Worth 579,206 710,521 567,483 597,969 513,530 616,805 515,891 8.04%
NOSH 234,496 234,495 234,497 234,498 234,488 234,526 234,496 0.00%
Ratio Analysis
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
NP Margin 11.54% 13.60% 9.40% 9.51% 9.74% 10.20% 8.79% -
ROE 41.26% 19.53% 61.99% 44.41% 36.18% 16.27% 66.08% -
Per Share
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
RPS 883.32 435.18 1,596.71 1,191.31 813.17 419.54 1,653.36 -34.23%
EPS 101.90 59.19 150.02 113.25 79.24 42.79 145.37 -21.14%
DPS 50.00 0.00 150.00 50.00 50.00 0.00 191.19 -59.20%
NAPS 2.47 3.03 2.42 2.55 2.19 2.63 2.20 8.04%
Adjusted Per Share Value based on latest NOSH - 234,519
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
RPS 883.30 435.18 1,596.69 1,191.30 813.13 419.59 1,653.33 -34.23%
EPS 101.90 59.19 150.02 113.25 79.24 42.79 145.37 -21.14%
DPS 50.00 0.00 150.00 50.00 50.00 0.00 191.19 -59.20%
NAPS 2.47 3.0299 2.42 2.55 2.1899 2.6303 2.20 8.04%
Price Multiplier on Financial Quarter End Date
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
Date 30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 -
Price 35.00 34.14 33.10 34.50 31.25 29.50 27.00 -
P/RPS 3.96 7.84 2.07 2.90 3.84 7.03 1.63 81.01%
P/EPS 34.35 57.68 22.06 30.46 39.44 68.94 18.57 50.85%
EY 2.91 1.73 4.53 3.28 2.54 1.45 5.38 -33.68%
DY 1.43 0.00 4.53 1.45 1.60 0.00 7.08 -65.67%
P/NAPS 14.17 11.27 13.68 13.53 14.27 11.22 12.27 10.10%
Price Multiplier on Announcement Date
30/06/10 31/03/10 31/12/09 30/09/09 30/06/09 31/03/09 31/12/08 CAGR
Date 26/08/10 21/04/10 25/02/10 29/10/09 27/08/09 15/04/09 26/02/09 -
Price 39.48 35.18 33.90 33.20 33.80 29.50 27.50 -
P/RPS 4.47 8.08 2.12 2.79 4.16 7.03 1.66 93.90%
P/EPS 38.74 59.44 22.60 29.32 42.66 68.94 18.92 61.45%
EY 2.58 1.68 4.43 3.41 2.34 1.45 5.29 -38.12%
DY 1.27 0.00 4.42 1.51 1.48 0.00 6.95 -67.89%
P/NAPS 15.98 11.61 14.01 13.02 15.43 11.22 12.50 17.84%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment